CSPC Pharmaceutical Group. has filed a patent for a method of treating peripheral T-cell lymphoma (PTCL) using a combination of drugs including mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine, and prednisone. The treatment is safe, tolerable, and shows promising results in achieving remission in treatment-naïve PTCL patients. GlobalData’s report on CSPC Pharmaceutical Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights CSPC Pharmaceutical Group Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on CSPC Pharmaceutical Group, Anti-bacterial thiazole derivatives was a key innovation area identified from patents. CSPC Pharmaceutical Group's grant share as of January 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.

A patent application (Publication Number: US20240024257A1) discloses a method for treating Peripheral T-cell Lymphoma (PTCL) by administering a combination of mitoxantrone liposome and cyclophosphamide, vincristine, and prednisone to patients in need. The method aims to improve the efficacy of the treatment regimen for PTCL by incorporating mitoxantrone liposome alongside standard chemotherapy drugs. The patent specifies the dosages and administration methods for each drug, emphasizing the importance of the sequential order of administration for optimal results.

Furthermore, the patent application includes claims for a composition designed for treating PTCL, comprising the specified drugs in a specific sequential order during each administration cycle. The composition utilizes a mitoxantrone liposome with a defined particle size and lipid bilayer composition to enhance the therapeutic effect. The patent also outlines the dosages and administration schedules for each drug within the composition, highlighting the importance of timing and dosage precision for successful treatment outcomes. Overall, the patent application provides a detailed method and composition for treating PTCL, focusing on the synergistic effects of combining mitoxantrone liposome with traditional chemotherapy drugs to improve patient outcomes in PTCL treatment.

To know more about GlobalData’s detailed insights on CSPC Pharmaceutical Group, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies